Ignite Creation Date:
2024-05-06 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04715360
Status:
UNKNOWN
Last Update Posted:
2021-01-20
First Post:
2021-01-15
Brief Title:
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
Sponsor:
Hayandra Peduli Foundation
Organization:
Hayandra Peduli Foundation
Study Overview
Official Title:
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The positive cases of coronavirus disease-2019 COVID-19 in Indonesia has been increasing rapidly since the first case found in March 2020 to date Coronavirus 2 SARS-CoV-2 virus disrupts human normal immune system resulting in uncontrolled inflammatory response Based on our research and experience in doing cell therapy for 9 years activated platelet-rich plasma PRP produces anti-inflammatory effects in inflammatory condition that is beneficial for tissue regeneration In this study we aimed to evaluate the potential of autologous activated platelet-rich plasma aaPRP and the outcomes for treating severe Coronavirus Disease-2019 COVID-19 patients in Intensive Care Unit ICU
Detailed Description:
PRP decreases IL-1β IL-6 IL-8 and TNFα inflammatory genes expression while also reduces IL-1β and TNFα inflammatory cytokines production PRP has also been showed to contain interleukin 1 receptor antagonist IL-1RA an anti-inflammatory cytokines that suppress IL-6 secretion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None